Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3–Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma
Guido Bisping(Boehringer Ingelheim (Germany)), Joachim Kienast(University of Münster)
Cited by 32
Related Papers
High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: Efficacy and safety*
|Critical Care Medicine|2006|188
Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin
|Thrombosis and Haemostasis|2006|85